Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) and Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Chugai Pharmaceutical and Aquestive Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Chugai Pharmaceutical | 0 | 3 | 1 | 1 | 2.60 |
| Aquestive Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
Aquestive Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 148.58%. Given Aquestive Therapeutics’ higher possible upside, analysts clearly believe Aquestive Therapeutics is more favorable than Chugai Pharmaceutical.
Insider & Institutional Ownership
0.0% of Chugai Pharmaceutical shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Chugai Pharmaceutical and Aquestive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Chugai Pharmaceutical | 35.63% | 24.91% | 20.67% |
| Aquestive Therapeutics | -162.33% | N/A | -57.35% |
Earnings & Valuation
This table compares Chugai Pharmaceutical and Aquestive Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Chugai Pharmaceutical | $8.41 billion | 8.81 | $2.91 billion | $0.96 | 23.47 |
| Aquestive Therapeutics | $48.84 million | 9.06 | -$83.78 million | ($0.64) | -5.50 |
Chugai Pharmaceutical has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Chugai Pharmaceutical has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.
Summary
Chugai Pharmaceutical beats Aquestive Therapeutics on 9 of the 15 factors compared between the two stocks.
About Chugai Pharmaceutical
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.
About Aquestive Therapeutics
Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
